Related Experiment Video
Updated: Mar 25, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Who should receive extended infusion beta-lactam therapy?
Christopher Roman1, Tia Solh, Kendra M Damer
1Christopher Roman is an assistant professor in the PA program at Butler University in Indianapolis, Ind. Tia Solh is an academic coordinator and assistant professor in the PA program at Philadelphia College of Osteopathic Medicine in Suwanee, Ga. Kendra M. Damer is an associate professor of pharmacy practice in Butler University's College of Pharmacy and Health Sciences. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Abstract:
The increasing prevalence of antibiotic-resistant bacteria challenges a clinician's ability to fight life-threatening infections. Administering beta-lactams via extended infusion may improve patient outcomes. This article discusses the underlying principles of this therapeutic approach and when it may be appropriate.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Inhibitors of Gram-positive Cell Wall Synthesis
Endocarditis IV: Nursing Management
Clinical Significance of Antibiotic Resistance
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Endocarditis III: Medical Management
